National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

VCL-CB01 vaccine
A vaccine consisting of two plasmids encoding the human cytomegalovirus (CMV) tegument phosphoprotein 65 (pp65), a major internal matrix protein, and glycoprotein B (gB), an important CMV component responsible for attachment and entry into cells, with immunostimulatory properties. Vaccination with VCL-CB01 may stimulate the host immune system to mount cellular and humoral immune responses against CMV positive cells, resulting in cell lysis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)




Previous:Vaqta, varenicline, vascular disrupting agent CYT997, Vasomax, vatalanib
Next:Vectibix, vector-peptide conjugated paclitaxel, Vectrin, VEGFR-2 inhibitor peptide CT-322, VEGFR1-1084 peptide vaccine

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov